COVID-19 Compound Repurposing Other

Cat. No. Product Name / Activity
6960 ABT 199
Exhibits binding to SARS-CoV-2 3CLpro in a virtual screen; selective and high affinity Bcl-2 inhibitor;
4274 AP 24534
Identified as targeting human proteins in the SARS-CoV-2 interactome; potent multi-kinase and pan-Bcr-Abl inhibitor
4139 Aprotinin
Inhibits SARS-CoV-2 infection in vitro; serine protease inhibitor
7235 Arbidol
Inhibits replication of SARS-CoV-2 in vitro; broad spectrum antiviral
6358 Atovaquone
Exhibits anti-MERS-CoV activity in vitro; DHODH inhibitor
3771 Azithromycin
Predicted to disrupt binding of SARS-CoV-2 spike protein to ACE2.
7222 Baricitinib
In silico modelling predicts inhibition of SARS-CoV-2 cell entry; highly potent JAK inhibitor
3193 Camostat mesylate
Inhibits entry of SARS-Cov-2 into lung cells; protease inhibitor
4455 Captopril
Targets human proteins in the SARS-CoV-2 interactome; ACE inhibitor
4109 Chloroquine diphosphate
Inhibits SARS-CoV-2 infection in vitro
6357 Ciclesonide
Inhibits replication fo SARS-CoV-2 in vitro; glucocorticoid
1364 Colchicine
Identified as a candidate for repurposing for COVID-19
0970 Cycloheximide
Exhibits anti-MERS-CoV activity in vitro; protein synthesis inhibitor
1101 Cyclosporin A
Inhibits coronavirus replication; cyclophilin inhibitor
7223 Dabrafenib mesylate
Targets human proteins in the SARS-CoV-2 interactome; potent and selective B-Raf, CDK16 and NEK9 inhibitor
6710 Darunavir
Predicted to bind PLpro of SARS-CoV-2; potent HIV protease inhibitor
6793 Dasatinib
Inhibits replication of SARS-CoV and MERS-CoV in vitro
1467 Daunorubicin hydrochloride
Identified as targeting human proteins in the SARS-CoV-2 interactome; DNA topoisomerase II inhibitor
1126 Dexamethasone
Anti-inflammatory glucocorticoid
4583 Digoxin
Exhibits anti-MERS-CoV activity in vitro; Na+/K+ ATPase inhibitor
3807 Disulfiram
SARS-Co-2 Mpro inhibitor; also reversibly stimulates SERCA Ca2+-ATPase
5245 Ebselen
Inhibits SARS-CoV-2 Mpro in vitro
3631 FK 506
Identified as targeting human proteins in the SARS-CoV-2 interactome; potent calcineurin inhibitor
3259 Gemcitabine hydrochloride
Inhibits replication of coronaviruses; DNA synthesis inhibitor
7227 GS 441524
Viral RNA-dependent RNA polymerase inhibitor; exhibits antiviral activity against SARS-CoV-2 in vitro
0931 Haloperidol hydrochloride
Targets human proteins in the SARS-CoV-2 interactome
5648 Hydroxychloroquine sulfate
Inhibits SARS-CoV-2 viral infection in vitro
5906 Imatinib mesylate
Inhibits replication of SARS-CoV and MERS-CoV in vitro; potent and selective v-Abl tyrosine kinase inhibitor
1708 Indomethacin
Identified as targeting human proteins in the SARS-CoV-2 interactome
1260 Ivermectin
Inhibits replication of SARS-Cov-2 in vitro; antiparasitic and antiviral
2959 Lercanidipine hydrochloride
Exhibits anti-MERS-CoV activity in vitro; CaV1.x blocker
3765 Linezolid
Identified as targeting human proteins in the SARS-CoV-2 interactome; antibiotic
0840 Loperamide hydrochloride
Inhibits replication of coronaviruses in vitro; peripherally acting μ opioid agonist and Ca2+ channel blocker
7052 Lopinavir
Inhibits SARS-CoV-2 replication in vitro; highly potent and selective HIV-1 protease inhibitor
3798 Losartan potassium
Reduces lung injury in a mouse model of SARS-CoV infection; Selective AT1 antagonist
2874 Luteolin
Binds SARS-CoV-2 main protease in molecular docking studies; also also anti-inflammatory, antioxidant and free radical scavenger
6819 Mefloquine hydrochloride
Exhibits antiviral activities against SARS-CoV-2; also Cx36 and Cx50 gap channel blocker
2864 Metformin hydrochloride
Identified as targeting human proteins in the SARS-CoV-2 interactome
3081 Nafamostat mesylate
Inhibits SARS-CoV-2 infection in vitro; serine protease inhibitor
3766 Nelfinavir mesylate
Exhibits anti-MERS-CoV activity in vitro; potent HIV-1 protease inhibitor
2583 Omeprazole
Enhances anti-SARS-CoV-2 activity of serine protease inhibitors
1076 Ouabain
Exhibits anti-MERS-CoV activity in vitro; Na+/K+ ATPase inhibitor
2992 PKC 412
Identified as targeting human proteins in the SARS-CoV-2 interactome
1125 Quercetin
Inhibits SARS-CoV main protease; also non-selective PI 3-kinase inhibitor
1292 Rapamycin
Inhibits MERS-CoV infection; mTOR inhibitor and immunosuppressant
7226 Remdesivir
Viral RNA-dependent RNA polymerase inhibitor; exhibits antiviral activity against SARS-CoV-2 in vitro
4501 Ribavirin
Inhibits cytopathic effect of SARS-CoV in vitro; guanosine analog and IMPDH inhibitor
5856 Ritonavir
Improves outcome in an animal model of MERS-CoV infection; HIV protease inhibitor
7064 Ruxolitinib
Targets human proteins in the SARS-CoV-2 interactome; potent and selective JAK1/JAK2 inhibitor
4418 Saquinavir mesylate
Modeling predicts inhibitor action at SARS-CoV-2 3CLpro; HIV protease inhibitor
3784 Sildenafil citrate
Reduces pulmonary pressure and edema; potent PDE5 inhibitor; orally active
0652 Thalidomide
Predicted to reduce cytokine release in SARS-CoV-2 infection; inhibits synthesis of TNF-α
2815 Valproic acid, sodium salt
Identified as targeting human proteins in the SARS-CoV-2 interactome
0654 Verapamil hydrochloride
Targets human proteins in the SARS-CoV-2 interactome; CaV1.x blocker